Back to top
more

INC Research Holdings, Inc. (SYNH)

(Delayed Data from NSDQ)

$47.27 USD

47.27
483,054

+0.56 (1.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Syneos Health (SYNH) New Partnership to Enhance Clinical Trials

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

Why Is Syneos Health (SYNH) Up 4.1% Since Last Earnings Report?

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Syneos Health (SYNH) Posts In-Line Q4 Earnings, Margins Up

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Syneos Health (SYNH) Matches Q4 Earnings Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base

Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.

    Syneos Health's (SYNH) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).

    Is Syneos Health (SYNH) a Good Value Investor Stock Now?

    Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.

    Here's Why You Should Invest in Syneos Health (SYNH) Now

    Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.

      New Strong Buy Stocks For November 17th

      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

      1Life Healthcare (ONEM) in Focus: Stock Moves 6.3% Higher

      1Life Healthcare (ONEM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

      Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up

      Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

      Syneos Health (SYNH) Tops Q3 Earnings Estimates

      Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

      Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth

      Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Syneos Health Banks on Essential Therapies Amid Coronavirus Woe

      Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.

      Syneos Health (SYNH) Down 8.2% Since Last Earnings Report: Can It Rebound?

      Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Syneos Health-Idorsia Collaborate to Launch Daridorexant in US

      Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.

      Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

      Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

      Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates

      Syneos Health (SYNH) delivered earnings and revenue surprises of 20.83% and 0.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

      Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline

      Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session

      Invitae (NVTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

      Senseonics Holdings (SENS) Catches Eye: Stock Jumps 5.7%

      Senseonics Holdings (SENS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

      Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session

      Allscripts (MDRX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

      10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session

      10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

      Syneos Health (SYNH) Up 9.3% Since Last Earnings Report: Can It Continue?

      Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down

      The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.